Pharmaceutical companies are undergoing a digital transformation. By experimenting with new initiatives, they are positioned to play a role in the revolution of healthcare. This transformation is driven by data from internal and external sources, including both -omic data and that from digital devices. Bio-IT World WEST, part of Molecular Medicine Tri-Conference, brings together all the stakeholders involved in this transformation.

Bio-IT World WEST is excited to return to San Francisco in 2020 with an expanded educational and networking program that promises to build on the success of our Boston-based 19th Annual Bio-IT World Conference & Expo. For the past 19 years, Bio-IT World Conference & Expo has established itself as a premier event focused on the innovative IT and informatics applications and enabling technologies that are driving the future of precision medicine. Bio-IT World Conference & Expo highlights the new frontiers in drug discovery & development, biomedical research, and clinical and healthcare initiatives made possible by these cutting-edge technologies. Join us at Bio-IT World WEST with an entirely new audience as we explore the Digitization of Pharma R&D, AI-Enabled Drug Discovery and Development, Emerging Technologies for Life Sciences, and Software Tools, Services, and Applications.

Final Agenda

Sunday, March 1

2:00 - 5:00 pm Afternoon Short Courses*

*Separate registration required

5:30 - 8:30 Dinner Short Courses*

*Separate registration required

Monday, March 2

8:00 - 11:00 am Morning Short Courses*

*Separate registration required

10:30 Conference Program Registration Open

KEYNOTE SESSION

11:45 Organizer’s Opening Remarks

Cindy Crowninshield, RDN, LDN, HHC, Executive Event Director, Cambridge Healthtech Institute

11:50 Chairperson’s Remarks

Allison Proffitt, Editorial Director, Bio-IT World

11:55 Keynote Sponsor Introduction (Sponsorship Opportunity Available)


12:10 pm KEYNOTE PRESENTATION: The AI Bubble and the Emerging Thinking Economy

Pietro Michelucci, PhD, Director, Human Computation Institute

12:40 KEYNOTE PANEL DISCUSSION: Data Quality in Human Computation Systems

Moderator: Allison Proffitt, Editorial Director, Bio-IT World

Panelists: Jennifer Couch, PhD, Chief, Structural Biology and Molecular Applications Branch, Division of Cancer Biology and Citizen Science Coordinator, National Cancer Institute

Devin Krotman, Director, Global Learning XPRIZE and IBM Watson AI XPRIZE

Vani Mandava, Director, Data Science Outreach, Microsoft Research

Pietro Michelucci, PhD, Director, Human Computation Institute

Ginger Tsueng, PhD, Scientific Outreach Project Manager, Department of Integrative, Structural and Computational Biology, The Scripps Research Institute

1:30 Bio-IT World WEST Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

2:05 Session Break

PLATFORMS TO FACILITATE DISCUSSION

2:20 Chairperson’s Remarks

Matthew Trunnell, Vice President and Chief Data Officer Director, Hutch Data Commonwealth

2:25 Establishing a Regional Data Commons

Matthew Trunnell, Vice President and Chief Data Officer Director, Hutch Data Commonwealth

The focus of the commons will be enabling discovery of and access to life sciences research data and healthcare data to advance research and innovation. That is, the principal initial stakeholders are life & health sciences researchers and technology organizations looking to innovate in this space. We currently have three workstreams: one around data discovery; one around privacy-preserving technologies (differential privacy, synthetic data, etc.) to facilitate access to clinical data; and a third around governance focused on streamlining the process of establishing data use agreements.

2:55 Turning WGS Genetic Testing into a Dialogue between Physicians and Labs with GenomeDiver

Christian Stolte, Data Visualization Designer, Informatics Research Innovation, New York Genome Center

Developed as part of the NYCKidSeq project, GenomeDiver fosters a dialogue between the clinician and genetic testing lab. The software leverages the physician’s knowledge of their patient by asking them to provide additional information to the lab, which then forms the basis for reanalysis. It delivers understandable information about mutations in the entire genome, using knowledge about functional variants coming from an increasing number of public sources, in particular the GTEx project.

3:25 Data-Driven Modeling Platform

Corrado Priami, PhD, President & CEO, COSBI

A user-friendly graphical platform is presented to integrate different data types in a single framework and to abstract them into actionable models. The platform speeds up research and development process and promotes data sharing.

3:55 Sponsored Presentation (Opportunity Available)

4:25 Refreshment Break and Transition to Plenary Keynote


PLENARY KEYNOTE SESSION

4:35 Welcome Remarks

Cindy Crowninshield, RDN, LDN, HHC, Executive Event Director, Cambridge Healthtech Institute

4:45 PLENARY KEYNOTE INTRODUCTION

Thomas Westerling-Bui, PhD, Senior Scientist, Regional Business Development, Aiforia

5:00 PLENARY KEYNOTE PRESENTATION: High-Performance Medicine

Eric Topol, MD, Founder and Director, Scripps Research Translational Institute (SRTI); Author, Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again

 

 

 

 

6:00 Grand Opening Reception in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

7:30 End of Day

Tuesday, March 3

7:30 am Registration Open and Morning Coffee

KEYNOTE SESSION

8:00 Organizer’s Remarks

Cindy Crowninshield, RDN, LDN, HHC, Executive Event Director, Cambridge Healthtech Institute

8:05 Chairperson’s Remarks

Sudeep Basu, PhD, Practice Leader, TechVision-Innovation Services, Frost & Sullivan

8:10 Keynote Sponsor Introduction (Sponsorship Opportunity Available)

8:25 KEYNOTE PRESENTATION: AI and Big Data Strategies in Accelerating Clinical Research for Faster Rare Disease Cures

Harsha K. Rajasimha, MS, PhD, Founder, Jeeva Informatics Solutions, Inc.; Founder, Organization for Rare Diseases India–USA (ORDIUSA); Co-Director, Rare Diseases Systems Biology Initiative, George Mason University

8:55 KEYNOTE PANEL DISCUSSION: Applications of AI Technologies in Pharmaceuticals: Facilitating Development of Therapeutics in Treating Rare Diseases

Moderator: Sudeep Basu, PhD, Practice Leader, TechVision-Innovation Services, Frost & Sullivan

Panelists: Tom Defay, Senior Director, R&D Strategy and Alliances, SPMD, Strategy, Program Management and Data Sciences, Alexion

Annastasiah Mhaka, PhD, President, The Alliance for Artificial Intelligence in Healthcare (AAIH)

Harsha K. Rajasimha, MS, PhD, Founder, Jeeva Informatics Solutions, Inc.; Founder, Organization for Rare Diseases India–USA (ORDIUSA); Co-Director, Rare Diseases Systems Biology Initiative, George Mason University

Christina Waters, PhD, President, CEO and Founder, RARE Science, Inc.

Additional Panelists to be Announced

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

ESTABLISHING A KNOWLEDGE NETWORK FOR RARE DISEASES

10:40 Chairperson’s Remarks

Ryan Leung, Vice President, Strategic Partnerships, SVAI, Research to the People

10:45 Rare Diseases: Starting at the Beginning

Michael Liebman, PhD, Managing Director, IPQ Analytics, LLC

Rare diseases, typically pediatric, are notoriously heterogeneous; they are difficult to diagnose and manage except in limited cases. We are establishing a “knowledge network” involving clinicians and researchers, patients and families, and implementing it within a platform that looks at the fetus and the effects of maternal lifestyle, environment and clinical history on the evolving stages of organ system development to evaluate where and how risk may develop for (rare) diseases. This involves an international collaboration and is targeting the identification of biomarkers and behaviors that indicate risk and may enable early detection and even prevention/mitigation. The platform initially examines lung development and disease risk, e.g., ARD and BPD, and will enable integration of existing studies and extension to other organ systems.

11:15 A Collaborative Open Source Platform for Patient-Partnered Research

Ryan Leung, Vice President, Strategic Partnerships, SVAI, Research to the People

The talk will focus on the growing importance of patients in healthcare research, strategies for public engagement and collaboration, and examples of our innovative platform for distributed, open-source biomedical discovery. It will feature highlights from our 4 patient research cases to date (neurofibromatosis 2, papillary renal cell carcinoma, undiagnosed metabolic disease, and neurofibromatosis) and our upcoming event (hypophosphotasia).

11:45 Sponsored Presentation (Opportunity Available)

12:15 pm Session Break

12:20 Bio-IT World WEST Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

2:00 Breakout Discussions in the Exhibit Hall

3:00 Transition to Conference Programs

CREATING IT STANDARDS TO UNLOCK DATA POTENTIAL

3:15 Chairperson’s Remarks

Chris Dwan, Senior Technologist and Independent Life Sciences Consultant

3:20 Lightweight, Practical Cross-Domain Metadata

Chris Dwan, Senior Technologist and Independent Life Sciences Consultant

It is increasingly clear that robust metadata management is one of the keys to unlocking the potential of biomedical data. Creating and enforcing usable standards for this metadata without stifling innovation and productivity or violating compliance requirements is a crucial balancing act with both technical and non-technical components. This talk will discuss real-world examples of metadata systems in use for sequencing, sample management, clinical phenotypes, diagnostic reports, and even analytical provenance chains from computational pipelines.

3:50 Building a Knowledge Factory to Retain and Reuse Tacit Knowledge

Alan Pruitt, Principal Project Manager, Knowledge Management, Pharma Technical Development, Genentech, Inc.

Every pharma company struggles with capturing knowledge trapped in the minds of its most talented employees. Multiple reorganizations, turnover, and retirements all contribute to the loss of tacit knowledge that the business needs to thrive. One way to combat this is to establish strong user communities centered on the critical technologies and processes. Doing this at scale for dozens or even hundreds of communities requires standard processes and robust IT tools to deliver value efficiently and reliably.

4:20 Sponsored Presentation (Opportunity Available)

4:50 Spring Fling Celebration in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

6:00 End of Day

6:30 - 9:30 Dinner Short Courses*

*Separate registration required

Wednesday, March 4

6:45 am Registration Open

7:00 BREAKFAST PANEL DISCUSSION: The Time is NOW: Creating Meaningful Change for Women in the Workplace (Sponsorship Opportunity Available)

Moderator: Robin Toft, Author of WE CAN, The Executive Woman’s Guide to Career Advancement; Founder and Chairman, Toft Group Executive Search

KEYNOTE SESSION

8:00 Organizer’s Remarks

Edel O’Regan, PhD, Vice President, Production, Cambridge Healthtech Institute

8:05 Chairperson’s Remarks

Joseph Ferrara, CEO, Boston Healthcare

8:10 Keynote Sponsor Introduction (Sponsorship Opportunity Available)


8:25 KEYNOTE PRESENTATION: The Value and Application of Informatics in Cancer Care Delivery

Debra A. Patt, MD, Vice President, Public Policy & Academic Affairs, Medical

Oncologist, Texas Oncology Cancer Center & Editor in Chief, Journal of Clinical Oncology-Clinical Cancer Informatics

8:55 KEYNOTE PANEL DISCUSSION: Pragmatic Use of Informatics in Cancer Care Delivery and Cancer Research: Big Data and AI Take on Cancer

Moderator: Joseph Ferrara, CEO, Boston Healthcare

Panelists: Mark Hulse, Chief Digital Officer, City of Hope

Debra A. Patt, MD, Vice President, Public Policy & Academic Affairs, Medical Oncologist, Texas Oncology Cancer Center & Editor in Chief, Journal of Clinical Oncology-Clinical Cancer Informatics

Nicholas Schork, PhD, Deputy Director of Quantitative Sciences, Distinguished Professor of Quantitative Medicine, The Translational Genomics Research Institute (TGen)

Robert P. Sebra, PhD, Associate Professor, Director of Technology Development & Genomics Core Facility, Icahn Institute, Icahn School of Medicine, Mount Sinai

Ajay Shah, PhD, Executive Director & Head of IT for Translational Medicine, Bristol-Myers Squibb

Paul A. Rejto, PhD, Vice President, Head of Translational Research, Pfizer Oncology R&D

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group

10:40 Chairperson’s Remarks

Zahra ‘Nasim’ Eftekhari, Senior Manager, Head of Applied AI and Data Science, City of Hope

CLINICAL CARE DECISION SUPPORT

10:45 From Development to Deployment: Lessons Learned from Application of Machine Learning in Oncology Decision Support

Zahra ‘Nasim’ Eftekhari, Senior Manager, Head of Applied AI and Data Science, City of Hope

CUTTING-EDGE ALGORITHMS FOR SEQUENCING

11:15 Degradation Normalization Improves Accuracy in RNA-Seq Analysis

Ji-Ping Wang, PhD, Professor of Statistics, Adjunct Professor of Molecular BioSciences, Faculty Member, NSF-Simons Center for Quantitative Biology, Northwestern University

RNA degradation affects RNA-seq quality when profiling transcriptional activities in cells. Transcript degradation is both gene- and sample-specific and is a common and significant factor that may bias the results in RNA-seq analysis. Most existing global normalization approaches are ineffective to correct for degradation bias. We propose a novel pipeline named DegNorm to adjust read counts for transcript degradation heterogeneity on a gene-by-gene basis while simultaneously controlling for the sequencing depth.

11:45 QuickIsoSeq: A Unified and Flexible Workflow on Isoform Quantification in Clinical RNA Sequencing

Shanrong Zhao, PhD, Director, Computational Biology, Pfizer

What’s wrong with featureCounts, a gene level counting tool? Why do we need isoform level quantification? QuickIsoSeq: implementation, functionalities and features.

12:15 pm PANEL DISCUSSION: Cutting-Edge Algorithms for scRNAseq

Moderator: Shanrong Zhao, PhD, Director, Computational Biology, Pfizer

Panelists: Rob Patro, PhD, Assistant Professor, Department of Computer Science, Center for Bioinformatics and Computational Biology, University of Maryland

Ji-Ping Wang, PhD, Professor of Statistics, Adjunct Professor of Molecular BioSciences, Faculty Member, NSF-Simons Center for Quantitative Biology, Northwestern University

12:45 Session Break

12:50 Bio-IT World WEST Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:20 Refreshment Break in the Exhibit Hall with Last Chance Poster Viewing, Speed Networking, Book Signing, and Meetup Group

FEATURED SESSION: DATA STRATEGIES FOR GENOMICS

2:00 Chairperson’s Remarks

Zhaoshi Jiang, PhD, Executive Director of Bioinformatics & Clinical Data Sciences, Gilead Sciences

2:05 Fake It ‘til You Make It (Reproducible): Synthetic Data Resources for Genomics

Geraldine A. Van der Auwera, PhD, Director of Outreach and Communications, Data Sciences Platform, Broad Institute

The computational reproducibility of published biomedical research is limited by data access restrictions, affecting not just researchers who wish to reuse published analysis code, but also tool developers and educators who lack suitable example data for testing and training. We present: 1) a prototype pipeline that wraps established open-source data simulation tools to generate publicly shareable synthetic sequence data at any scale; and 2) a plan to develop community resources.

2:35 Progress in Diagnosing Rare Disease Patients Leveraging NLP and Genomic Sequencing

Tom Defay, Senior Director, R&D Strategy and Alliances, SPMD, Strategy, Program Management and Data Sciences, Alexion

Diagnosing patients with rare disease is challenging. Whole exome and whole genome sequencing have improved our diagnostic abilities but can still fall short due to our lack of understanding of which mutations are most likely to be the cause of disease. By combining phenotypic information automatically extracted from the patient’s EMR with a patient’s genome sequence, we have developed a system for prioritizing which mutations may be most significant and proposing possible diagnoses. Advances on this approach will be discussed.

3:05 Drug Targets with Genomic Support

J. Wade Davis, PhD, ACOS Research Fellow, Director, Computational Genomics, Genomics Research Center (GRC), AbbVie

3:35 Close of Conference